TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26081066

Group type: EXPERIMENTAL
Intervention: NT‐proBNP concentrations in women who developed CVD (81 ng/l [50 to 147])
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: NT‐proBNP in the highest quartile compared to the lowest quartile
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: NT‐proBNP as a continuous variable
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: NT‐proBNP per 1-SD change in Ln(NT‐proBNP) for cardiovascular death
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: NT‐proBNP per 1-SD change in Ln(NT‐proBNP) for stroke
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: NT‐proBNP per 1-SD change in Ln(NT‐proBNP) for myocardial infarction
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: NT‐proBNP added to traditional risk co-variables
Number of subjects: 480
Study: 22092534

Group type: EXPERIMENTAL
Intervention: Error-reduced (ER) training program
Number of subjects: 216

Group type: COMPARATOR
Intervention: Error-strewn (ES) training program
Number of subjects: 216
Study: 21298384

Group type: EXPERIMENTAL
Intervention: Cisplatin-based regimens
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based regimens
Number of subjects: 106
Study: 19695188

Group type: EXPERIMENTAL
Intervention: Cold autoblood cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 30
Study: 16732837

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study: 14746870

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the motor cortex contralateral to the CRPS-affected side
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study: 11335736

Group type: EXPERIMENTAL
Intervention: Nasal synchronized intermittent mandatory ventilation (nSIMV) at a rate of 12 bpm with pressure set to achieve at least 12 cm H(2)O and a peak end expiratory pressure of 6 cm H(2)O.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP) at 6 cm H(2)O.
Number of subjects: 54
Study: 9243585

Group type: EXPERIMENTAL
Intervention: Walking exercise program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 8273922

Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sufentanil (S)
Number of subjects: 70
Study: 3717716

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate aerosol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isoproterenol hydrochloride aerosol
Number of subjects: 29
Study: 29944164

Group type: EXPERIMENTAL
Intervention: High SPF sunscreen applied at 1.3 mg/cm2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High SPF sunscreen applied at 2.0 mg/cm2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High SPF sunscreen applied at 0.75 mg/cm2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unprotected control skin
Number of subjects: 0
Study: 27304988

Group type: EXPERIMENTAL
Intervention: Vibration intervention (small vibration devices placed on one hand and one foot, activated in 6 hour ON/OFF sequences for a total of 24 hours)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Vibration intervention
Number of subjects: 1
Study: 24956119

Group type: EXPERIMENTAL
Intervention: MBL-HCV1 treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 21542734

Group type: EXPERIMENTAL
Intervention: 1% alendronate gel
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 66
Study: 20064018

Group type: EXPERIMENTAL
Intervention: Functional Relaxation (FR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enhanced Medical Care (EMC)
Number of subjects: 80
Study: 17578858

Group type: EXPERIMENTAL
Intervention: Patients with peripheral vestibular disease
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patients with unilateral canal paresis without balance symptoms
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patients with bilateral vestibular loss
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 110
Study: 15670539

Group type: EXPERIMENTAL
Intervention: Trimetazidine plus sildenafil (sildenafil 100 mg 1 hour before sexual intercourse, trimetazidine 20 mg 3 times a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitrates (20 mg 3 times a day)
Number of subjects: 38
Study: 12075057

Group type: EXPERIMENTAL
Intervention: Fumagillin (60 mg per day orally for two weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9861597

Group type: EXPERIMENTAL
Intervention: Diet-Plus-Exercise Training (D + EX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diet Alone (D)
Number of subjects: 22
Study: 7530801

Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: EBVD
Number of subjects: 157

Group type: COMPARATOR
Intervention: MBVD
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ABVD or EBVD
Number of subjects: 157

Group type: COMPARATOR
Intervention: ABVD, EBVD, MBVD
Number of subjects: 157
Study: 2245418

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training before chemotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Coping style (blunting)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Coping style (monitoring)
Number of subjects: 48
Study: 702130

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31985313

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 0

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study: 31732149

Group type: EXPERIMENTAL
Intervention: Xhance® 186 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Xhance® 372 μg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Flonase® 400 μg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Flovent® HFA 440 μg
Number of subjects: 120
Study: 28341685

Group type: EXPERIMENTAL
Intervention: Computerised decision aid (DA)
Number of subjects: 12
Study: 25720848

Group type: EXPERIMENTAL
Intervention: Batroxobin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23243239

Group type: EXPERIMENTAL
Intervention: BD supplemented with 0.5% HSCAS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BD supplemented with 2.5 mg of AFB(1)/kg of feed and 0.5% HSCAS
Number of subjects: 100

Group type: COMPARATOR
Intervention: BD supplemented with 2.5 mg of AFB(1)/kg of feed
Number of subjects: 100
Study: 20628180

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 250 mg given thrice weekly
Number of subjects: 99

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 99
Study: 19841338

Group type: EXPERIMENTAL
Intervention: Prednisolone for 2 weeks (monotherapy)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prednisolone for 2 weeks plus Ginkgo biloba for 4 weeks (combination therapy)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 71
Study: 17075269

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained-release theophylline 5-8 mg/kg (dry syrup) or 100-200 mg (tablet) twice daily
Number of subjects: 0
Study: 14657228

Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (arm B) - 70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and fluorouracil
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard radiotherapy (arm A) - 70 Gy in 35 fractions
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (arm B)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard radiotherapy (arm A)
Number of subjects: 226
Study: 11230586

Group type: COMPARATOR
Intervention: No cooling (rectal temperature = 37.0 +/- 0.2 degrees C, n = 15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minimally cooled (rectal temperature 36.5 degrees C to 36 degrees C, n = 6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mildly cooled (rectal temperature 35.9 degrees C to 35.5 degrees C, n = 6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mildly cooled (rectal temperature 35 +/- 0.5 degrees C, n = 6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mildly cooled (rectal temperature 34.5 +/- 0.5 degrees C, n = 7)
Number of subjects: 40
Study: 9880884

Group type: EXPERIMENTAL
Intervention: Application of two endoloops with additional manual stump sinking
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Application of endo-cutter
Number of subjects: 150

Group type: COMPARATOR
Intervention: Application of two endoloops without stump sinking
Number of subjects: 150
Study: 7977125

Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (average INR 1.72)
Number of subjects: 75
Study: 2535298

Group type: EXPERIMENTAL
Intervention: Sufentanil, 5 micrograms/kg, IV with succinylcholine, 1 mg/kg, IV
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etomidate, 0.4 mg/kg, IV with succinylcholine, 1 mg/kg, IV
Number of subjects: 20
Study: 1095310

Group type: EXPERIMENTAL
Intervention: Clotrimazole therapy
Number of subjects: 202

Group type: COMPARATOR
Intervention: Nystatin therapy
Number of subjects: 202
Study: 30595354

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (250 mg daily) plus MPH-ER (36 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fluvoxamine (250 mg daily) plus placebo
Number of subjects: 44
Study: 29739386

Group type: EXPERIMENTAL
Intervention: 60-min games-based activity (basketball)
Number of subjects: 39
Study: 26509366

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg/d during 7 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 24561207

Group type: EXPERIMENTAL
Intervention: ACUSEAL patching
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vascu-Guard patching
Number of subjects: 200
Study: 23073950

Group type: EXPERIMENTAL
Intervention: High-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at high levels)
Number of subjects: 3418

Group type: COMPARATOR
Intervention: Standard-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at standard levels)
Number of subjects: 3418

Group type: EXPERIMENTAL
Intervention: High-dose multivitamin supplementation
Number of subjects: 3418

Group type: COMPARATOR
Intervention: Standard-dose multivitamin supplementation
Number of subjects: 3418
Study: 21708060

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 14 days
Number of subjects: 1141
Study: 16675714

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Blood glucose testing (BGT)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Family relationships
Number of subjects: 127
Study: 15934992

Group type: EXPERIMENTAL
Intervention: IV magnesium (0.2 mg Mg per mL acid citrate dextrose‐A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12425542

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Combination of Lactobacillus spp. and bifidobacteria
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 10075273

Group type: EXPERIMENTAL
Intervention: Delavirdine in combination with zidovudine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo in combination with zidovudine
Number of subjects: 89
Study: 9150972

Group type: EXPERIMENTAL
Intervention: Vertical hand‐transmitted repetitive shock vibration with exponential decays and hanning waveforms at 2.8 ms‐2 r.m.s. for various shock repetition rates (2 to 64 shocks per second)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shock repetition rates of 2 to 64 shocks per second
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current standards for assessing severity of hand‐transmitted vibration
Number of subjects: 0
Study: 2024973

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg) administered as a 1-h infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg) administered as an oral tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral dosage form of ofloxacin
Number of subjects: 20
Study: 7004771

Group type: EXPERIMENTAL
Intervention: Nova-T IUD
Number of subjects: 815

Group type: COMPARATOR
Intervention: Copper-T-200 IUD
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Both IUDs
Number of subjects: 815
Study: 6344900

Group type: EXPERIMENTAL
Intervention: M&B 22,948 (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29730707

Group type: EXPERIMENTAL
Intervention: Nanostructured carbonated hydroxyapatite (cHA) microspheres with BDGF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nanostructured carbonated hydroxyapatite (cHA) microspheres alone
Number of subjects: 10
Study: 30402473

Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) 400 μg/kg.b.w
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) 800 μg/kg.b.w
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) 1600 μg/kg.b.w
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 26823611

Group type: EXPERIMENTAL
Intervention: 2.9% THC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6.7% THC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (approximately 0.065% peak breath alcohol concentration)
Number of subjects: 18
Study: 24445087

Group type: EXPERIMENTAL
Intervention: Disposable radiation-absorbing surgical drapes
Number of subjects: 36
Study: 22492127

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFNβ‐1b) 250 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19747410

Group type: EXPERIMENTAL
Intervention: Fermented dairy product containing Lactobacillus casei DN-114001 (200 g/d)
Number of subjects: 1072
Study: 17621025

Group type: EXPERIMENTAL
Intervention: Discectomy without fusion (ACD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Discectomy with intervertebral fusion (ACDF)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Discectomy with intervertebral fusion and instrumentation (ACDFI)
Number of subjects: 42
Study: 16325660

Group type: EXPERIMENTAL
Intervention: ACR clinical classification criteria
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ACR clinical plus radiographic classification criteria
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA) control group
Number of subjects: 90
Study: 12701728

Group type: EXPERIMENTAL
Intervention: 8-channel CIS strategy (833 pps/channel, 75 micros/phase)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 12-channel CIS strategy (+/- 1,400 pps/channel, 21 micros/phase)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 16-channel CIS strategy (+/- 1,400 pps/channel, 21 micros/phase)
Number of subjects: 9
Study: 10472396

Group type: EXPERIMENTAL
Intervention: Educational intervention including information on doping, discussions on nutritional supplements, drug simulating role play, and self-medication information.
Number of subjects: 476

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 476
Study: 8598548

Group type: EXPERIMENTAL
Intervention: Kunitz trypsin inhibitor
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bowman‐Birk inhibitor
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (intraduodenal saline)
Number of subjects: 6
Study: 1932482

Group type: EXPERIMENTAL
Intervention: 100 mg cimetidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7140260

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 74
Study: 30651610

Group type: EXPERIMENTAL
Intervention: Routine genomic sequencing of neonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard newborn screening
Number of subjects: 0
Study: 27852036

Group type: EXPERIMENTAL
Intervention: E39+250mcg GM-CSF (VG)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1000mcg E39 (VG)
Number of subjects: 51
Study: 26016936

Group type: EXPERIMENTAL
Intervention: Alternative Perfusion Solution (APS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Steen group (SG)
Number of subjects: 16
Study: 24039213

Group type: EXPERIMENTAL
Intervention: Sunglasses worn during daytime in addition to topical aqueous nasal budesonide and loratadine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Topical aqueous nasal budesonide and loratadine
Number of subjects: 39
Study: 21507529

Group type: EXPERIMENTAL
Intervention: Orthogeriatric Unit (OGU)
Number of subjects: 506
Study: 17851462

Group type: EXPERIMENTAL
Intervention: Protein hydrolysates (pea, rice, soy, gluten, whey, egg) with 0.2 g hydrolysate per kg body weight and 0.2 g maltodextrin per kg body weight
Number of subjects: 8

Group type: COMPARATOR
Intervention: Maltodextrin alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gluten protein hydrolysate
Number of subjects: 8
Study: 17823625

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both pioglitazone and atorvastatin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 15064633

Group type: EXPERIMENTAL
Intervention: Cineole (two 100‐mg capsules three times daily)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cineole
Number of subjects: 152
Study: 12692603

Group type: EXPERIMENTAL
Intervention: Etoposide (E) at 800 mg/m²
Number of subjects: 10

Group type: COMPARATOR
Intervention: Etoposide phosphate (EP) at 910 mg/m²
Number of subjects: 10
Study: 10073771

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated circuit (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Heparin-coated and Uncoated circuits)
Number of subjects: 30
Study: 8927524

Group type: EXPERIMENTAL
Intervention: Lightguide spectrophotometry measuring haemoglobin oxygenation (SO2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison with normal subjects (N=12)
Number of subjects: 41
Study: 1911014

Group type: EXPERIMENTAL
Intervention: Propofol 56 x 10(‐3) mol litre‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10% Intralipid
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 8
Study: 6785974

Group type: EXPERIMENTAL
Intervention: sulphinpyrazone
Number of subjects: 186

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 186
Study: 31756730

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 136
Study: 31221225

Group type: EXPERIMENTAL
Intervention: Western medicine and conventional acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Western medicine and mind-regulating acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 29746218

Group type: EXPERIMENTAL
Intervention: Active warming (carbon fiber resistive system - W-500D + 190 × 50 cm)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Passive warming (blanket, socks etc. for at least 20 minutes during preoperative period)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no active or passive warming)
Number of subjects: 90
Study: 26932738

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day for 6 months)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 24236828

Group type: EXPERIMENTAL
Intervention: Otelixizumab (3.1 mg over 8 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22300416

Group type: EXPERIMENTAL
Intervention: Preoperative preparation (including a photo file, demonstration of equipment using a role-modelling approach, and a tour)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Preoperative preparation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard practice (control group with no specific preoperative education)
Number of subjects: 73
Study: 20367660

Group type: EXPERIMENTAL
Intervention: Ablation of residual potentials as add-on therapy to circumferential pulmonary vein ablation (CPVA) + pulmonary vein electrical isolation (PVI), n = 49
Number of subjects: 102

Group type: COMPARATOR
Intervention: No ablation of residual potentials, n = 53
Number of subjects: 102
Study: 18670855

Group type: EXPERIMENTAL
Intervention: Intraoperative gamma probe
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy (LS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Blue dye
Number of subjects: 32
Study: 15932362

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12559644

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam followed by Phenytoin
Number of subjects: 0
Study: 10498160

Group type: EXPERIMENTAL
Intervention: Long-term diuretic therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: No diuretic therapy (Control)
Number of subjects: 34
Study: 8869791

Group type: EXPERIMENTAL
Intervention: AN-69 membrane
Number of subjects: 11

Group type: COMPARATOR
Intervention: SPAN membrane
Number of subjects: 11